- Home
- LBRX vs NXP Comparison
LBRX vs NXP Comparison
Compare LBRX & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LBRX | NXP |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 890.4M |
| IPO Year | 2025 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LBRX | NXP |
|---|---|---|
| Price | $44.41 | $14.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $46.60 | N/A |
| AVG Volume (30 Days) | ★ 388.7K | 138.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $13.89 |
| 52 Week High | $49.14 | $14.65 |
Technical Indicators
Market Signals| Indicator | LBRX | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 56.26 |
| Support Level | $20.71 | $14.23 |
| Resistance Level | N/A | $14.51 |
| Average True Range (ATR) | 3.19 | 0.10 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 69.16 | 100.00 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.